Fentanyl sublingual - Orexo

Drug Profile

Fentanyl sublingual - Orexo

Alternative Names: Abstral; EN-3267; Fentanyl citrate sublingual tablets; Fentanyl transmucosal - Orexo; KW-2246; OX-20; Rapinyl

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Orexo
  • Developer Galena Biopharma; Kyowa Hakko Kirin; Kyowa Kirin International; Paladin Labs
  • Class General anaesthetics; Opioid analgesics; Piperidines; Small molecules
  • Mechanism of Action Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Cancer pain

Most Recent Events

  • 19 Jan 2017 Sentynl Therapeutics has been acquired by Zydus Cadila
  • 03 May 2016 Re-launched for Cancer pain by Sentnyl Therapeutics in USA (Sublingual)
  • 03 May 2016 The US label for sublingual fentanyl carries a black box warning related to the risk of respiratory depression, medication errors and abuse potential
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top